Axxin provides platforms and diagnostic products for biomedical applications that bridge the gap from research to market with world leading innovation, capability and cost effectiveness.
The company's goal is to take the cost and complexity out of point of care diagnostics and near patient applications. The company has extensive experience in instrument design, industrial design, sensor technologies and has applied these to molecular and lateral flow applications.
Axxin has established itself as an early leader in commercializing diagnostic delivery systems in partnership with leading biomedical and pharmaceutical companies.
Molecular Medicine Tri-Conference, produced by Cambridge Healthtech Institute, is the predominant event on the West Coast focused on integrating the entire spectrum of drug development. CHI's Molecular Medicine Tri-Conference event is unique in that it brings together the therapeutic and diagnostic aspects of the industry in one place. Come and meet Axxin's CEO, Andrew Lysikatos at booth 312.
Join thousands of your peers in Philadelphia for the 2017 AACC/CSCC Annual Meeting and Clinical Lab Expo, the Largest Clinical Lab Exposition in the World. See new science and new technology in all areas of clinical diagnostics, automation, information systems, point-of-care, OEM, and biotech. Conference is located at the Pennsylvania Convention Center. Come and meet the Axxin Team at booth 4654 or 5951.
Technological advances in next generation diagnostics are driving growth and innovation in healthcare. Rapid and precise diagnosis is essential for personalized medicine and will change the way value is assessed and compensated in the healthcare system. This meeting offers a comprehensive view of the changing landscape of diagnostics and brings together the key players in the field. Come and meet Axxin's CEO, Andrew Lysikatos at Booth 301.
This conference will provide an overview of the point-of-care (POC) testing landscape, from novel technologies to regulatory approval. Experts in these fields will share their views on point-of-care in the clinical setting. The aim of this meeting is to bring together life science researchers that work at the interface between biology and chemistry to discuss problems, highlight solutions and facilitating collaborations. Also, we frame the role of POC in the expanding Global Health field and highlight opportunities existing in many parts of the world. This conference covers POC Detection, POC Diagnostics and POC Treatment as part of the Comprehensive Coverage of this Expanding Field. The POC testing field is expanding focused not only on infectious disease diagnostics (which represents approximately 80% of the marketplace) but also with cancer and cardiovascular disease focus.
Come and meet Axxin's CEO, Andrew Lysikatos at Booth 5. Contact email@example.com.